i1d
Scrapping NHS learning disability target ‘risks disabled people’s life expectancy’
Officials say that ‘streamlining’ targets will help deliver faster treatment for hundreds of thousands of patients – but ...
AFP1d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...